When asked about behavioral support, 56% of employed adults said they would self-pay for a GLP-1 if their employer offered a ...
Major US health insurers have eliminated roughly 11% of prior authorization requirements and introduced new ...
Most patients initiated full-dose ibrutinib, while reduced starting doses clustered in older, more comorbid, poorer ECOG ...
Clinically meaningful MG-ADL response (≥2-point reduction) occurred in 69% of treated patients, exceeding the 53% response ...
The Value Operator is an orchestrator who centrally owns contract translation, governance, data configuration, and ...
Enrollment occurred across two Dallas hospitals; exclusions included transplant, LVAD, inotropes at discharge, existing meal ...
Despite a 24% drop since 2015, over 4 million Americans remain on long-term opioids, and they’re older, on Medicare, and ...
Microsimulation comparing three mt-sDNA rounds versus one colonoscopy over 10 years incorporated real-world adherence, test ...
Targeted maintenance therapy with gilteritinib (Xospata; Astellas) following allogeneic hematopoietic stem cell ...
Analysis of 3.24 million commercially insured patients (55.3 million claims) found a significant downward trend in annual ...
Generic dapagliflozin is indicated to lower heart failure hospitalization risk in type 2 diabetes with established ...
In this episode of Managed Care Cast, Ella Hohmann speaks with Douglas Marks, MD, breast medical oncologist and associate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results